Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.42 |
| ▸ | MGAM | O43451 | 3/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | SI | P14410 | 3/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18354586 | 0.68 | SLC9A1 (0.41) | HSD11B1GAAHPGDKMT2ASLC9A1 | |
| SCHEMBL1691202 | 0.60 | THRA (0.56) | GAAHPGDELANEMAPT | |
| SCHEMBL6260923 | 0.59 | MGAM (0.53) | HSD11B1MGAMAMY1AGAASI | |
| SCHEMBL3242580 | 0.58 | MAPT (0.56) | GAAHPGDKMT2ACYP1A2MAPT | |
| Benzoic Acid SCHEMBL11126820 | 0.58 | TSHR (0.64) | HPGDKMT2AMAPTCYP2C9 | |
| Benzoic Acid SCHEMBL27397300 | 0.58 | TSHR (0.64) | HPGDKMT2AMAPTCYP2C9 | |
| Benzoic Acid SCHEMBL2032078 | 0.58 | TSHR (0.64) | HPGDKMT2ACYP1A2MAPTCYP2C9 | |
| Benzoic Acid SCHEMBL6934526 | 0.58 | TSHR (0.64) | HPGDKMT2ACYP1A2MAPTCYP2C9 | |
| SCHEMBL12770991 | 0.58 | ENPP3 (0.73) | GAAKMT2AMAPT | |
| SCHEMBL496975 | 0.58 | ELANE (0.70) | MGAMAMY1AGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914732-B2 | Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2018-03-13 | — | — | US | disclosed |
| US-9914732-B2 | Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2018-03-13 | — | — | US | disclosed |
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | SNCA, DDT, DRD1 | HSD11B1 366/4885MGAM 2160/4885AMY1A 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.